MAPK14 and prostate cancer: Indeed, a luciferase reporter system visualized the in vivo ERK and p38 MAPK activities and provided direct evidence of p38/ERK activity as an indicator of DCCs in various types of cancer, including breast cancer, prostate cancer, melanoma, and fibrosarcoma8.